66 research outputs found
A Terraced Scanning Superconducting Quantum Interference Device Susceptometer with Sub-Micron Pickup Loops
Superconducting Quantum Interference Devices (SQUIDs) can have excellent spin
sensitivity depending on their magnetic flux noise, pick-up loop diameter, and
distance from the sample. We report a family of scanning SQUID susceptometers
with terraced tips that position the pick-up loops 300 nm from the sample. The
600 nm - 2 um pickup loops, defined by focused ion beam, are integrated into a
12-layer optical lithography process allowing flux-locked feedback, in situ
background subtraction and optimized flux noise. These features enable a
sensitivity of ~70 electron spins per root Hertz at 4K.Comment: See http://stanford.edu/group/moler/publications.html for an
auxiliary document containing additional fabrication details and discussio
Science and Ideology in Economic, Political, and Social Thought
This paper has two sources: One is my own research in three broad areas: business cycles, economic measurement and social choice. In all of these fields I attempted to apply the basic precepts of the scientific method as it is understood in the natural sciences. I found that my effort at using natural science methods in economics was met with little understanding and often considerable hostility. I found economics to be driven less by common sense and empirical evidence, then by various ideologies that exhibited either a political or a methodological bias, or both. This brings me to the second source: Several books have appeared recently that describe in historical terms the ideological forces that have shaped either the direct areas in which I worked, or a broader background. These books taught me that the ideological forces in the social sciences are even stronger than I imagined on the basis of my own experiences.
The scientific method is the antipode to ideology. I feel that the scientific work that I have done on specific, long standing and fundamental problems in economics and political science have given me additional insights into the destructive role of ideology beyond the history of thought orientation of the works I will be discussing
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Comment in
Lowering the High Cost of Cancer Drugs--III. [Mayo Clin Proc. 2016]
Lowering the High Cost of Cancer Drugs--I. [Mayo Clin Proc. 2016]
Lowering the High Cost of Cancer Drugs--IV. [Mayo Clin Proc. 2016]
In Reply--Lowering the High Cost of Cancer Drugs. [Mayo Clin Proc. 2016]
US oncologists call for government regulation to curb drug price rises. [BMJ. 2015
Highlights From the Annual Meeting of the American Epilepsy Society 2022
With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia
It’s Not Only Rents: Explaining the Persistence and Change of Neopatrimonialism in Indonesia
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials
Aims:
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials.
Methods and Results:
Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594).
Conclusions:
GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation
THE ECONOMIC AND SOCIOLOGICAL BACKGROUND, TRAINING AND EXPERIENCE OF SUPERINTENDENTS SERVING NEBRASKA CLASS II AND III DISTRICTS DURING 1968-1969
Abstract not availabl
- …